Short communication: Genetic variations of SLC2A9 in relation to Parkinson's disease

Translational Neurodegeneration

Volumn 2, Issue 1, 2013, Pages

  Gao, Jianjun ^a   Xu, Hong ^a   Huang, Xuemei ^b   Chen, Honglei ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUTE CARRIER FAMILY 2 MEMBER 9 GENE;

EID: 84883602992     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-2-5     Document Type: Article

References (11)

1. Weisskopf M, O'Reilly E, Chen H, Schwarzschild M, Ascherio A. Plasma Urate and Risk of Parkinson's Disease. Am J Epidemiol 2007, 166(5):561-567. 10.1093/aje/kwm127, 2391073, 17584757.
2. Chen H, Mosley TH, Alonso A, Huang X. Plasma Urate and Parkinson's Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2009, 169(9):1064-1069. 10.1093/aje/kwp033, 2727240, 19299404.
3. Ascherio A, LeWitt PA, Xu K, et al. Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. Arch Neurol 2009, 66(12):1460-1468. 2795011, 19822770.
4. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Smith GD. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2007, 27(8):1133-1163.
5. Doring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008, 40(4):430-436. 10.1038/ng.107, 18327256.
6. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40(4):437-442. 10.1038/ng.106, 18327257.
7. Gao J, Xu H, Weinberg C, et al. An exploratory study on the CHRNA3-CHRNA5-CHRNB4 cluster, smoking, and Parkinson's disease. Neurodegener Dis 2011, 8(5):296-299. 10.1159/000323190, 3121544, 21228559.
8. Dehghan A, Köttgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008, 372(9654):1953-1961. 10.1016/S0140-6736(08)61343-4, 2803340, 18834626.
9. Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010, 3(6):523-530. 10.1161/CIRCGENETICS.109.934455, 3371395, 20884846.
10. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008, 5(10):e197. 10.1371/journal.pmed.0050197, 2561076, 18842065.
11. Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H. Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 2012, 16(1):89-95. 10.1007/s10157-011-0532-z, 22038265.